Premium
Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study
Author(s) -
Napolitano M.,
Fabbrocini G.,
Scalvenzi M.,
Blasio C.,
Stingeni L.,
Patruno C.
Publication year - 2020
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14260
Subject(s) - dupilumab , atopic dermatitis , medicine , polypharmacy , retrospective cohort study , observational study , dermatology , monoclonal , monoclonal antibody , immunology , antibody
Summary Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence in both children (15–30%) and adults (2–10%), but limited data are available for older people. Elderly patients form a challenging group, as multiple comorbidities, associated polypharmacy and failures with previous treatments are common. We performed a retrospective observational study on elderly (≥ 65 years) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the interleukin‐4 and ‐13 receptor approved for the treatment of moderate‐to‐severe AD in adults.